STOCK TITAN

Heartbeam, Inc. - BEAT STOCK NEWS

Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.

HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.

HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.

Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.

One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.

HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.

Latest News: Source: HeartBeam, Inc.

  • ------
  • ------
  • ------
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
none
-
Rhea-AI Summary
HeartBeam, Inc. has appointed Deborah Castillo, PhD, as Vice President of Regulatory Affairs. Castillo brings extensive experience in regulatory affairs and quality assurance for medical devices and diagnostics, with a focus on cardiovascular diseases and neuroscience. She will lead HeartBeam's regulatory affairs function and support the company's clinical development and commercialization efforts for its novel HeartBeam AIMIGo™ Platform Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) announces the appointment of Michael R. Jaff, DO, a renowned Vascular Physician and Researcher, to its board of directors. Dr. Jaff brings extensive clinical and industry experience, having held key positions at Boston Scientific Corporation and Harvard Medical School. This move strengthens HeartBeam's board with Dr. Jaff's expertise in vascular medicine and innovation, aligning with the company's focus on developing advanced cardiac technology, including the 3D-vector electrocardiogram (VECG) platform for home use. The appointment reflects HeartBeam's commitment to leveraging top talent for advancing its cardiac technology solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
Rhea-AI Summary
HeartBeam, a cardiac technology company, has closed its secondary offering of 16,666,666 shares of common stock, raising $23.2 million. The funding will support upcoming clinical and regulatory milestones for its HeartBeam AIMIGo™ system and prepare for commercialization in 2024. The company will focus on obtaining FDA clearances for its VECG device and the system's ability to synthesize an ECG. HeartBeam plans to demonstrate the performance of its AIMIGo platform through clinical trials in 2023 and aims to launch commercially in 2024. The company will also focus on defining market segments, developing intellectual property, and adding Key Opinion Leaders to its Medical Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
none

FAQ

What is the current stock price of Heartbeam (BEAT)?

The current stock price of Heartbeam (BEAT) is $2.39 as of December 24, 2024.

What is the market cap of Heartbeam (BEAT)?

The market cap of Heartbeam (BEAT) is approximately 63.7M.

What does HeartBeam, Inc. do?

HeartBeam, Inc. develops high-resolution ambulatory ECG solutions for detecting and monitoring cardiac disease outside traditional healthcare settings.

What is unique about HeartBeam's technology?

HeartBeam's technology includes a credit card-sized ECG device and a cloud-based diagnostic system that performs as well as top cardiologists in diagnosing heart attacks.

How does HeartBeam's iCardiologist application work?

The iCardiologist application uses AI and machine learning to continuously improve its diagnostic accuracy and predictive capabilities, assisting cardiologists in patient analysis.

What is VECG technology?

VECG stands for Vector Electrocardiography, a proprietary and patented platform developed by HeartBeam to provide higher-resolution ECG solutions.

Has HeartBeam's technology been validated?

Yes, studies by Harvard Medical School faculty have shown that HeartBeam's performance is equal to or better than world-class cardiologists in diagnosing heart attacks.

Is HeartBeam seeking FDA clearance?

Yes, HeartBeam is currently seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

What are the benefits of HeartBeam's ECG solutions?

HeartBeam's solutions offer accessible, high-resolution cardiac monitoring useful outside of traditional healthcare settings, providing early detection and monitoring of cardiac conditions.

Can HeartBeam's technology locate a heart attack?

Yes, the technology can help cardiologists locate a heart attack on a 3D model of the heart using personalized diagnostic thresholds and novel ECG markers.

How is HeartBeam improving cardiac care?

HeartBeam is improving cardiac care by developing practical, high-resolution ECG solutions that provide critical diagnostic tools accessible outside traditional healthcare environments.

Where can I find the latest news on HeartBeam, Inc.?

The latest news and updates on HeartBeam, Inc. can be found on StockTitan and other financial news platforms.

Heartbeam, Inc.

Nasdaq:BEAT

BEAT Rankings

BEAT Stock Data

63.73M
18.98M
29.25%
8.73%
0.47%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States of America
SANTA CLARA